Adding to the interest in Galectin on Monday, analysts Aegis Capital reiterated their “buy” rating
on the stock. In April, analysts at MLV & Co. put out a “buy”
rating on GALT and boosted their price target from $20 to $27.
Click here to receive updates on Galectin Therapeutics developments: http://www.tdmfinancial.com/emailassets/galt/galt_landing.php
Galmed has not disclosed the date for completing its PK/food effect
study, but it cannot be too far off in the distance in order to initiate
the mid-stage trial of aramchol that it has planned this year.
Intercept and Galectin both have data anticipated late next month (or
perhaps later in Intercept’s case), the type of data that can have
market-moving potential. The stock prices of the companies have mostly
undulated in unison, including all three trading higher since
Intercept’s PBC Fast Track news late in May and jumping at the opening
bell Monday after Galectin released its pre-clinical data, so upcoming
news in the coming weeks is likely to draw further attention to the
SOURCE: Emerging Growth LLC